⌕
Olema Oncology · OLMA · Nasdaq
Tenet 55 · Mixed
Compare
$7.36−2.65%At closeTenet 55 · Mixed
$7.36−0.20 (−2.65%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Olema Oncology (OLMA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 16, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies…

● Seeking AlphaNov 12, 2026 · 18:19 ET
Olema Pharmaceuticals, Inc. (OLMA) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

Olema Pharmaceuticals, Inc. ( OLMA ) Stifel 2026 Healthcare Conference 2026 November 11, 2026 10:40 AM EST Company Participants Sean Bohen - President, CEO & Director Conference Call Participants Laura Prendergast - Stif…

● GlobeNewsWireNov 12, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Olema Oncology Announces Corporate Name Change

SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discover…

● Defense WorldNov 11, 2026 · 01:29 ET
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Has Consensus Target Price of $40.60

Shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the thirteen ratings firms that are presently covering the company, MarketBeat.com repo…

● GlobeNewsWireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results

SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializ…

● GlobeNewsWireNov 3, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializ…

● GlobeNewsWireNov 2, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializ…

● Zacks Investment ResearchOct 16, 2026 · 10:46 ET
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.…

● GlobeNewsWireOct 2, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializ…

● Seeking AlphaSep 15, 2026 · 16:41 ET
Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Seeking AlphaSep 10, 2026 · 17:57 ET
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

● GlobeNewsWireSep 2, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commerciali…

● GlobeNewsWireAug 31, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializ…

● Defense WorldAug 31, 2026 · 04:31 ET
66,163 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark and Lunn Investment Management Ltd. bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) during the second quarter, according to its most recent filing with the SEC. The firm bought 66,163 shares…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just OLMA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.